share_log

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target

Benzinga ·  Aug 8, 2023 06:15

HC Wainwright & Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment